Medtronic announced Friday that FDA has approved the the first MR-conditional cardiac resynchronization therapy defibrillators (CRT-Ds) for the treatment of heart failure in the U.S. The Medtronic ...
PLATINIUM, released simultaneously in both Europe and Japan by LivaNova (formerly Sorin Group), will protect patients from avoidable replacement surgeries and the inherent risk of complications.
Please provide your email address to receive an email when new articles are posted on . Among the features of the new European Society of Cardiology guideline on pacing and cardiac resynchronization ...
The EchoCRT Study Will Investigate the Life-Saving Benefits of Cardiac Resynchronization Therapy in Patients with Heart Failure Who Currently Do Not Receive Device Therapy BERLIN, Germany & LAKE ...
ST. PAUL, Minn. St. Jude Medical, Inc. today announced regulatory approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) and the launch of the Fortify(TM) ST implantable cardioverter ...
ABBOTT PARK, Ill., Feb. 18, 2020 /PRNewswire/ -- Abbott (NYSE: ABT) today announced it has received CE Mark for the new Gallantâ„¢ implantable cardioverter defibrillator (ICD) and cardiac ...
MINNEAPOLIS - Medtronic, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved an expanded indication for biventricular (BiV) pacing with Medtronic cardiac resynchronization ...
NEW YORK/CHICAGO, June 23 (Reuters) - Early intervention with Boston Scientific Corp's implantable devices, called cardiac resynchronization therapy, can slow the progression of heart failure, ...
San Francisco, CA - When a heart-failure patient has a defibrillator-equipped cardiac resynchronization therapy (CRT-D) device, antitachycardia pacing (ATP) is preferable to a shock for the treatment ...
On the heels of a unanimous FDA panel recommendation in March for an expanded indication of Boston Scientific's (Natick, Massachusetts) cardiac resynchronization therapy defibrillators (CRT-Ds), ...
A combination defibrillator and cardiac resynchronization device reduced deaths by nearly one-third in patients with mild heart failure in a study that was terminated early on Monday because of its ...
The company identified 7 studies that incorporated a cost-effectiveness analysis. It did not rely on these economic studies for its model, but the structure of the de novo model is similar to that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results